1 completed, 1 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow ErbB Receptors: new trials by email Literature Review of ErbB Receptors trials Research Report on ErbB Receptors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors ISU104, Cetuximab - Solid Tumor | Phase 1 | Unknown | ISU Abxis Co., Ltd. | 33 | 2018-04-27 | 2021-05-06 |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation MEK162, Erlotinib - Lung Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2013-12-30 | 2023-01-19 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · ISU Abxis Co., Ltd. (1)
South Korea (1) · United States (1)
Jaehyeon Juhn, Ph.D (1) · Jhanelle Gray, M.D. (1)